RE: Results from DSMB16 Oct 2025 09:46
I do agree with Alde's latest point. My biggest gripe throughout the past few years has been the lack of comms and consideration of those invested, who have been funding the company (with the constant dilutions). I've raised the point many times, and the response is usually 'but the science is good'. It isn't a zero-sum game....you can have great science AND follow it up with regular comms and PR, it doesn't have to be a dichotomy of one or the other. In every company I'm invested in, there is a constant mix of updates, interviews, press releases, RNS. Whilst I accept Hemo is a relatively smaller company, it's publicly listed and regular comms costs next to nothing but does wonders for sentiment, and sentiment drives trading.